Simeon George

Dr. George joined SR One in 2007 and is CEO of the fund. He earned his MD and MBA from the University of Pennsylvania School of Medicine / Wharton School and BA from Johns Hopkins University. Previously, Dr. George worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, recently acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.